Weight-Loss Drug Tirzepatide Shows Promise for Treating Sleep Apnea

New study reveals significant reduction in sleep apnea symptoms and potential decrease in CPAP machine dependency.

Clinical trials demonstrate tirzepatide's efficacy in reducing breathing interruptions during sleep.
Researchers observed notable improvements in patients' sleep quality and overall health.
The drug may become the first pharmaceutical treatment targeting the underlying causes of sleep apnea.
Eli Lilly has applied for FDA approval to expand tirzepatide's use for sleep apnea treatment.
Study participants also experienced weight loss and reduced cardiovascular risk factors.